St. Jude (STJ) Gets CE Mark for Ellipse ICD
Tweet
Share
E-mailGet Alerts STJ Hot Sheet
Join SI Premium – FREE
St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, today announced CE Mark Approval of the Ellipse implantable cardioverter defibrillator (ICD). Designed with feedback from more than 200 physicians from around the world, the Ellipse ICD provides the benefits of advanced features and power in the industry’s smallest high-energy ICD.
ICDs are advanced implantable cardiac devices that treat potentially lethal, abnormally fast heart rhythms (ventricular tachycardia or ventricular fibrillation) that often lead to sudden cardiac death (SCD).
ICDs are advanced implantable cardiac devices that treat potentially lethal, abnormally fast heart rhythms (ventricular tachycardia or ventricular fibrillation) that often lead to sudden cardiac death (SCD).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- Walmart opens its 100th EV fast-charging site in Monument, CO
- WiMi proposes quantum convolutional neural network for data tasks
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
